- Location
oncology drug
"-
VBL Therapeutics Has Secured Fast Track Status From The US FDA
Nov 29, 2013VBL Therapeutics has secured fast track status from the US Food and Drug Administration (FDA) for its lead oncology drug VB-111, for prolongation of survival in patients with Recurrent Glioblastoma Multiforme (rGBM). VB-111 was already ...
-
Boston Strategics Has Entered Into a New Drug Development Partnership with FPHU
Nov 29, 2013US-based research and development biotechnology firm Boston Strategics has entered into a new drug development partnership with Fujifilm Pharmaceuticals USA (FPHU), a global pharmaceutical development center of Japan's Fujifilm Corporation. ...
Tags: Oncology Drugs, Fujifilm Pharma
-
Rexahn Has Entered Into an Exclusive Licensing Agreement with The University of Maryland
Jul 18, 2013Clinical stage biopharma company Rexahn Pharmaceuticals has entered into an exclusive licensing agreement with the University of Maryland, Baltimore (UMB), for a novel drug delivery platform, which targets the delivery of chemotherapeutic ...
Tags: Rexahn Pharma, Oncology Drug
-
Molecular Response Introduced TargetX Platform for The Rapid Discovery
Apr 11, 2013Molecular Response has introduced TargetX platform for the rapid discovery and validation of new oncology targets. The integrated platform, which features 144,000 living tumor specimens, genomic databases and patient derived tumor models, ...
Tags: TargetX platform, oncology targets
-
Crown Bioscience and Horizon Discovery Entered Into a Two Year Collaboration Agreement
Apr 5, 2013US-based drug discovery and development service company Crown Bioscience and Horizon Discovery have entered into a two year collaboration agreement to provide combined solutions for in vivo model development. Under the partnership, ...
-
Critical Outcome Has Received a Patent for Its Advanced Oncology Drug Candidate
Dec 5, 2012Critical Outcome Technologies has received a patent for its advanced oncology drug candidate, from the US Patent and Trademark Office. The patent covers the synergistic effects of combination therapies containing COTI-2 and members of ...
Tags: oncology drug, COTI-2, anti cancer agents
-
Thomson Reuters Has Launched a New Mobile Oncology Decision Support Solution
Dec 4, 2012Thomson Reuters' Intellectual Property & Science division has launched a new mobile oncology decision support solution to support R&D focused pharmaceutical majors. The solution provides a series of oncology-based clinical dashboards that ...
Tags: Thomson Reuters, new mobile oncology decision support solution
-
CSD and Intrinsiq Have Formed Partnership with The Launch of an Integrated Solution
Dec 4, 2012Cegedim Strategic Data (CSD) and IntrinsiQ have formed partnership with the launch of an integrated solution for monitoring promotional activity and its impact on Oncology drug utilization in the US market. The integrated oncology data ...
Tags: Barts Health NHS Trust, OnBase, ECM, EPR
-
Hospira Has Announced The US Re-Launch of Oxaliplatin Injection
Nov 29, 2012Hospira has announced the US re-launch of oxaliplatin injection, a generic version of Sanofi's chemotherapy medication Eloxatin. Hospira will initially offer the solution form of oxaliplatin injection in 50mg and 100mg single-use vials, ...
Tags: oxaliplatin injection, Sanofi's chemotherapy medication, oncology drug
-
Vernalis Has Reached a Research Milestone with Servier
Nov 28, 2012Vernalis has reached a research milestone as part of the oncology drug discovery alliance with French pharmaceutical company, Servier. Under the drug discovery program, Vernalis will receive a payment of €0.5m from Servier on ...
Tags: drug discovery platforms, oncology drug discovery, undisclosed oncology
